Track topics on Twitter Track topics that are important to you
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well giving tacrolimus together with mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation with or without fludarabine followed by donor stem cell transplant for hematologic cancer.
- Determine the incidence of grades III and IV graft-versus-host disease (GVHD) in patients with hematologic malignancies treated with immunosuppression comprising tacrolimus and mycophenolate mofetil after nonmyeloablative conditioning comprising total body irradiation with or without fludarabine and allogeneic stem cell transplantation.
- Determine the incidence of chronic extensive GVHD in patients treated with these regimens.
- Determine the incidence of graft rejection in patients treated with these regimens.
- Determine the 1-year overall survival of patients treated with these regimens.
- Determine the incidence of grades II-IV acute GVHD in patients treated with these regimens.
- Determine the rate of disease progression in patients treated with these regimens.
- Determine the rate of relapse-related mortality in patients treated with these regimens.
- Determine the rate and duration of steroid use for the treatment of chronic GVHD in patients treated with these regimens.
OUTLINE: This is a multicenter study.
- Conditioning: Patients who have not undergone a prior autologous hematopoietic stem cell transplantation within the past 6 months receive fludarabine IV on days -4 to -2. All patients undergo total body irradiation on day 0.
- Allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo allogeneic PBSCT on day 0.
- Immunosuppression: Patients receive mycophenolate mofetil IV or orally twice daily on days 0-27. Patients also receive tacrolimus IV or orally twice daily on days -3 to 56 followed by a taper to day 180.
Patients are followed at 6, 12, and 18 months and then annually for 5 years.
PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study within 3 years.
Masking: Open Label, Primary Purpose: Supportive Care
Chronic Myeloproliferative Disorders
graft-versus-tumor induction therapy, fludarabine phosphate, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, radiation therapy
Huntsman Cancer Institute at University of Utah
Salt Lake City
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:54:10-0400
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells. Giving chemotherapy or ...
Immunosuppression With Mycophenolate Mofetil and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies or Metastatic Renal Cell Carcinoma
RATIONALE: Giving different schedules of mycophenolate mofetil and cyclosporine may be effective in reducing graft-versus-host disease in patients undergoing donor peripheral stem cell tra...
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of tumor cells. It a...
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth ...
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, and antithymocyte globulin before a donor stem cell transplant helps stop the growth of tumor cells. It may a...
We report comparative efficacy between high-dose cyclophosphamide (HDCyC), low-dose cyclophosphamide (LDCyC), mycophenolate mofetil (MMF) and rituximab in patients with lupus nephritis (LN).
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
Most patients with chronic lymphocytic leukaemia relapse after initial therapy combining chemotherapy with rituximab. We assessed the efficacy and safety of rituximab maintenance treatment versus obse...
We evaluated inosine monophosphate dehydrogenase (IMPDH) 1 and IMPDH2 pharmacogenetics in 247 recipient-donor pairs after nonmyeloablative hematopoietic cell transplant (HCT) recipients. Patients were...
Cure of acute leukemia after transplantation is mediated by the grafted cells. We investigated the graft-versus-leukemia effect (GVL) in patients with cutaneous acute graft-versus-host disease (GVHD) ...
Allogeneic haemopoietic stem cell transplantation (HSCT) is increasingly used to treat haematological malignant diseases via the graft-versus-leukaemia (GvL) or graft-versus-tumour effects. Although i...
The induction of prolonged survival and growth of allografts of either tumors or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunized donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
The immune responses of a host to a graft. A specific response is GRAFT REJECTION.
Hypoxic conditions in tumor cells due to the tumor outgrowing its blood supply. It is associated with increased METASTASIS and resistance to RADIOTHERAPY and DRUG THERAPY.
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...